| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1742.8 | 1695.4 | 1424.9 |
| Other income | 111.5 | 63.2 | 44.0 |
| Total income | 1854.3 | 1758.5 | 1468.9 |
| Profit before exceptional items & tax | 505.8 | 386.5 | 288.3 |
| Exceptional items | 0.0 | 24.3 | 0.0 |
| Profit before tax | 505.8 | 362.1 | 288.3 |
| Net profit | 366.7 | 261.5 | 186.5 |
| Operating margin | 27.3% | 20.6% | 19.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +96.60% |
|---|---|
| Net profit, quarter on quarter | +40.20% |
| Revenue, year on year | +22.30% |
BSE results filing, NSE: GLAND. Figures extracted from the filing.
Gland Pharma Ltd: key numbers
- Share price
- ₹2,917.20
- Market cap
- ₹48,137 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 42.6×Sector 50.4×
- Promoter holding
- 51.77%-0.06% QoQ
- FII holding
- 8.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Merger & Restructuring Worth ₹4.81 Cr
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
- Value
- ₹4.81 Cr
Gland Pharma Acquisition Worth ₹4.76 Cr
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
- Value
- ₹4.76 Cr
- Execution
- By October 31, 2026
Gland Pharma Employee Stock Options
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma Legal & Regulatory
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
- Value
- ₹0.14 Cr
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma Investor Presentation: Key Takeaways
Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
- Call
- Guides 15% growth